bcl-2 gene therapy exacerbates excitotoxicity

Hum Gene Ther. 1999 Jul 1;10(10):1715-20. doi: 10.1089/10430349950017716.

Abstract

The protooncogene bcl-2 can block neuronal death from both naturally occurring apoptosis and exogenous insults. bcl-2 is therefore a promising candidate for the prevention of excitotoxic neuronal death. Using an adeno-associated viral vector, we delivered the bcl-2 gene to the ganglion cell layer of the rat eye. We hypothesized that infection with bcl-2 would protect ganglion cells against excitotoxic cell death. However, retinal infection with bcl-2 increased ganglion cell susceptibility to both axonal injury and intravitreal NMDA. Our study--intended to explore the possibility of bcl-2 transduction as an in vivo therapeutic approach--revealed a deleterious effect of bcl-2 transduction.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cell Survival / drug effects
  • Dependovirus
  • Excitatory Amino Acid Agonists / pharmacology*
  • Ganglia / cytology
  • Ganglia / drug effects*
  • Gene Expression
  • Genetic Therapy / methods
  • Genetic Vectors
  • Green Fluorescent Proteins
  • Humans
  • Luminescent Proteins / genetics
  • N-Methylaspartate / pharmacology*
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Excitatory Amino Acid Agonists
  • Luminescent Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Green Fluorescent Proteins
  • N-Methylaspartate